Alios, Vertex indication worldwide license agreement to develop new hepatitis C combination medicines Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc sildenafil citrate review . Today announced an exclusive worldwide licensing contract which will add two specific nucleotide analogues to Vertex’s hepatitis C portfolio. The compounds, which were discovered by Alios and so are referred to as ALS-2200 and ALS-2158, have shown in in vitro studies to be potent inhibitors of the hepatitis C virus polymerase, an enzyme needed for replication of the virus.
Aripiprazole lauroxil was well tolerated in the analysis generally, and the observed safety profile of aripiprazole lauroxil was very similar compared to that reported with oral aripiprazole. The most common adverse events in the analysis were insomnia, akathisia and headache. Related StoriesAristada extended release injection approved to treat adults with schizophreniaNew evaluation finds illogical thoughts as most predictive of schizophrenia riskResearchers match certain schizophrenia symptoms to features of the human brain's anatomyStudy Design The phase 3, randomized, multicenter, double-blind, placebo-controlled study was designed to assess the efficacy, safety and tolerability of aripiprazole lauroxil in individuals experiencing acute exacerbation of schizophrenia.